Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. More Details
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Vapotherm's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VAPO's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: VAPO exceeded the US Medical Equipment industry which returned 13.7% over the past year.
Return vs Market: VAPO exceeded the US Market which returned 10.9% over the past year.
Price Volatility Vs. Market
How volatile is Vapotherm's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StSome Vapotherm (NYSE:VAPO) Shareholders Are Down 10%
6 months ago | Simply Wall StVapotherm, Inc. Just Reported, And Analysts Assigned A US$17.33 Price Target
7 months ago | Simply Wall StVapotherm, Inc. (NYSE:VAPO) Insiders Increased Their Holdings
Is Vapotherm undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VAPO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VAPO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VAPO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: VAPO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VAPO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VAPO is overvalued based on its PB Ratio (4.7x) compared to the US Medical Equipment industry average (3.7x).
How is Vapotherm forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VAPO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VAPO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VAPO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VAPO's revenue (0.8% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: VAPO's revenue (0.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VAPO's Return on Equity is forecast to be high in 3 years time
How has Vapotherm performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VAPO is currently unprofitable.
Growing Profit Margin: VAPO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VAPO is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.
Accelerating Growth: Unable to compare VAPO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VAPO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: VAPO has a negative Return on Equity (-33.89%), as it is currently unprofitable.
How is Vapotherm's financial position?
Financial Position Analysis
Short Term Liabilities: VAPO's short term assets ($187.9M) exceed its short term liabilities ($27.3M).
Long Term Liabilities: VAPO's short term assets ($187.9M) exceed its long term liabilities ($42.5M).
Debt to Equity History and Analysis
Debt Level: VAPO's debt to equity ratio (33.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if VAPO's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VAPO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VAPO has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 12.1% each year.
What is Vapotherm current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VAPO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VAPO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VAPO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VAPO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VAPO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joe Army (56 yo)
Mr. Joseph F. Army, also known as Joe, CPA has been the Chief Executive Officer and President of Vapotherm, Inc. since June 26, 2012. Mr. Army served as the Chief Executive Officer and President of Salient ...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD3.00M) is about average for companies of similar size in the US market ($USD3.07M).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||8.25yrs||US$3.00m||2.63% |
|Vice President of Operations||6.5yrs||US$816.88k||0.33% |
|Senior VP & Chief Commercial Officer||no data||US$807.85k||0.042% |
|no data||no data||no data|
|CFO, Senior VP||8.08yrs||US$277.31k||0.46% |
|Vice President of Legal & Compliance||no data||no data||no data|
|Vice President of Human Resources||4.25yrs||no data||0.12% |
Experienced Management: VAPO's management team is seasoned and experienced (7.3 years average tenure).
|CEO, President & Director||8.25yrs||US$3.00m||2.63% |
|Independent Chairman of the Board||7.92yrs||US$183.74k||0.37% |
|Independent Director||10.08yrs||US$153.74k||0% |
|Independent Director||2.92yrs||US$153.74k||0.48% |
|Independent Director||2.92yrs||US$141.24k||0.078% |
|Independent Director||7.5yrs||US$141.24k||0.024% |
|Independent Director||6.58yrs||US$148.74k||0% |
|Independent Director||0.67yr||no data||0.0096% |
Experienced Board: VAPO's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VAPO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.1%.
Vapotherm, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Vapotherm, Inc.
- Ticker: VAPO
- Exchange: NYSE
- Founded: 1993
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$650.251m
- Shares outstanding: 25.57m
- Website: https://www.vapotherm.com
Number of Employees
- Vapotherm, Inc.
- 100 Domain Drive
- New Hampshire
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VAPO||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Nov 2018|
|VA21||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2018|
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory d ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/25 06:43|
|End of Day Share Price||2020/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.